Core Viewpoint - The company reported a modest increase in revenue and a significant rise in net profit for the third quarter, indicating a positive financial performance despite a challenging market environment [1] Financial Performance - The company's operating revenue for the first three quarters reached 609 million yuan, representing a year-on-year growth of 2.59% [1] - The net profit attributable to shareholders of the listed company was 87.38 million yuan, showing a year-on-year increase of 20.92% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 69.67 million yuan, reflecting a year-on-year growth of 11.48% [1]

Core Viewpoint - The company reported a modest increase in revenue and a significant rise in net profit for the third quarter, indicating a positive financial performance despite a challenging market environment [1] Financial Performance - The company's operating revenue for the first three quarters reached 609 million yuan, representing a year-on-year growth of 2.59% [1] - The net profit attributable to shareholders for the same period was 87.38 million yuan, showing a year-on-year increase of 20.92% [1] - The net profit after deducting non-recurring gains and losses was 69.67 million yuan, reflecting a year-on-year growth of 11.48% [1]

二、董事会会议审议情况 经与会董事认真审议，一致同意通过如下决议： （一）审议通过《关于公司<2025 年第三季度报告>的议案》 经审议，董事会认为：公司《2025 年第三季度报告》的编制程序符合法律、 行政法规和中国证券监督管理委员会、深圳证券交易所的相关法律法规、规范性 文件的规定，报告内容真实、准确、完整地反映了公司的实际情况，不存在任何 虚假记载、误导性陈述或者重大遗漏。 本议案已经公司董事会审计委员会审议通过。 证券代码:301257 证券简称:普蕊斯 公告编号:2025-063 普蕊斯（上海）医药科技开发股份有限公司 第三届董事会第十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 普蕊斯（上海）医药科技开发股份有限公司（以下简称"公司"）第三届董事 会第十六次会议于 2025 年 10 月 28 日在公司会议室以现场会议及通讯相结合的 形式召开，本次会议通知及会议资料已于 2025 年 10 月 24 日以专人送达、电子 邮件的方式发出，会议应出席董事 9 人，实际参与会议的董事 9 人，其中董事马 林、刘 ...

证券代码：301257 证券简称：普蕊斯 公告编号：2025-064 普蕊斯（上海）医药科技开发股份有限公司 关于 2025 年前三季度利润分配方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、公司 2025 年前三季度利润分配方案为：以现有公司总股本 79,004,770 股为基数，向全体股东每 10 股派发现金红利 0.68 元（含税），合计派发现金股 利 5,372,324.36 元（含税），本次不进行资本公积转增股本，不送红股。 公司分别于 2025 年 10 月 24 日、10 月 28 日召开了第三届董事会审计委员 会第十四次会议、第三届董事会第四次独立董事专门会议和第三届董事会第十六 次会议，审议通过了《关于 2025 年前三季度利润分配方案的议案》，同意公司 实施 2025 年前三季度利润分配方案。本次利润分配方案在公司 2024 年年度股东 大会授权范围内，无需提交股东会审议。 二、2025 年前三季度利润分配方案基本情况 根据公司 2025 年第三季度财务报告（未经审计），公司 2025 年前三季度实 现归属于上市 ...

普蕊斯（上海）医药科技开发股份有限公司 2025 年第三季度报告 证券代码：301257 证券简称：普蕊斯 公告编号：2025-062 普蕊斯（上海）医药科技开发股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会及董事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担 个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度财务会计报告是否经过审计 □是 否 1 普蕊斯（上海）医药科技开发股份有限公司 2025 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同 | 年初至报告期末 | 年初至报告期末 | | --- | --- | --- | --- | --- | | | | 期增减 | | 比上年同期增减 | | 营业收入（元） | 218,910,71 ...

创新药概念股午后持续拉升，诺思格20cm涨停，普蕊斯、康芝药业涨超10%，泰格医药、康龙化成、 贝达药业涨幅居前。 ...

Core Points - The stock price of Puris has increased by 5.15% to 47.99 CNY per share, with a total market capitalization of 3.791 billion CNY, and a cumulative increase of 6.04% over the past four days [1] - Puris (Shanghai) Pharmaceutical Technology Development Co., Ltd. was established on February 22, 2013, and went public on May 17, 2022, focusing on technology development, transfer, consultation, and services in the pharmaceutical sector, with 100% of its revenue coming from services [1] Fund Holdings - According to data, one fund under Nuoan Fund holds Puris as a significant position, with Nuoan Jingxin Mixed Fund (002145) owning 50,300 shares, accounting for 5.29% of the fund's net value, making it the fourth-largest holding [2] - The fund has generated a floating profit of approximately 118,200 CNY today and 130,800 CNY during the four-day increase [2] - Nuoan Jingxin Mixed Fund was established on December 8, 2015, with a current scale of 45.606 million CNY, achieving a year-to-date return of 57.06% and a one-year return of 57.19% [2]

Core Viewpoint - The stock price of Puris has increased by 5.15% to 47.99 CNY per share, with a total market capitalization of 3.791 billion CNY, reflecting a cumulative increase of 6.04% over the past four days [1] Group 1: Company Overview - Puris (Shanghai) Pharmaceutical Technology Development Co., Ltd. was established on February 22, 2013, and went public on May 17, 2022 [1] - The company is located at 500 Guangdong Road, 23rd Floor, World Trade Building, Huangpu District, Shanghai [1] - Puris's main business involves technology development, transfer, consulting, and services in the pharmaceutical field, with 100% of its revenue coming from services [1] Group 2: Fund Holdings - Morgan Stanley's fund holds a significant position in Puris, with the "Morgan Stanley Youyue Anhe Mixed A" fund (009893) owning 80,300 shares, representing 6.23% of the fund's net value, making it the fourth-largest holding [2] - The fund has generated a floating profit of approximately 188,700 CNY today and 208,800 CNY during the four-day increase [2] - The fund was established on September 24, 2020, with a current size of 29.6292 million CNY and has achieved an 18.21% return this year, ranking 4747 out of 8155 in its category [2]

Investment Rating - The report maintains a positive outlook on the pharmaceutical sector, indicating an "Overweight" rating for the industry, suggesting it is expected to outperform the overall market [32]. Core Insights - The report highlights that the Shenwan Pharmaceutical and Biological Index increased by 0.6% this week, while the Shanghai Composite Index rose by 2.9% and the Wind All A (excluding financials and petrochemicals) increased by 3.7% [4][6]. - The pharmaceutical sector's overall valuation stands at 30.4 times earnings, ranking 9th among 31 Shenwan primary industries [4][8]. - Significant collaborations and clinical trial results were reported, including a $11.4 billion global strategic partnership between Innovent Biologics and Takeda Pharmaceutical, which includes a $1.2 billion upfront payment [5][13]. - Key clinical trial results presented at the 2025 ESMO conference showed promising outcomes for several drugs, indicating advancements in treatment efficacy for various cancers [14][18][19]. Market Performance - The report details the performance of various sub-sectors within the pharmaceutical industry, with notable increases in medical devices (+0.2%), medical consumables (+1.7%), and medical research outsourcing (+5.5%), while traditional Chinese medicine and other biological products saw declines [4][8]. - The report also notes that 99 A-share pharmaceutical companies released their Q3 2025 earnings, with a total revenue of 94.15 billion yuan, reflecting a 1.3% year-on-year increase [20][22]. Key Events - The report mentions that Bairui Tianheng has passed the Hong Kong Stock Exchange hearing and is in the process of listing its H-shares [12]. - The report emphasizes the importance of the 2025 ESMO conference, where several companies presented significant clinical data, enhancing their market visibility and potential investment attractiveness [14][17][18]. Company Recommendations - The report recommends focusing on innovative drug sectors and companies with improving performance in medical devices and upstream sectors, including companies like Hengrui Medicine, Changchun High-tech, and Mindray Medical [5][20].

Market Overview - On October 23, the medical services sector rose by 0.19% compared to the previous trading day, with Bid Pharma leading the gains [1] - The Shanghai Composite Index closed at 3922.41, up 0.22%, while the Shenzhen Component Index closed at 13025.45, also up 0.22% [1] Top Gainers in Medical Services - Bid Pharma (688073) closed at 71.15, up 5.27% with a trading volume of 11,500 lots and a transaction value of 799.13 million [1] - ST Zhongzhu (600568) closed at 2.02, up 5.21% with a trading volume of 400,000 lots and a transaction value of 794.03 million [1] - Other notable gainers include *ST Biology (000504) at 9.50, up 2.48%, and Kanglong Chemical (300759) at 31.44, up 1.55% [1] Top Losers in Medical Services - Haitai Bio (300683) closed at 32.06, down 7.15% with a trading volume of 136,900 lots and a transaction value of 440 million [2] - Innovative Medical (002173) closed at 22.32, down 5.10% with a trading volume of 639,200 lots and a transaction value of 143.2 million [2] - Other significant decliners include Chengda Pharmaceutical (301201) at 32.70, down 3.77%, and Heyuan Bio (688238) at 7.49, down 2.60% [2] Capital Flow Analysis - On the same day, the medical services sector experienced a net outflow of 637 million from institutional investors, while retail investors saw a net inflow of 723 million [2][3] - The overall capital flow indicates that while institutional investors were pulling back, retail investors were actively buying into the sector [2][3] Individual Stock Capital Flow - For Aier Eye Hospital (300015), there was a net outflow of 20.59 million from institutional investors, while retail investors contributed a net inflow of 231,940 [3] - Kanglong Chemical (300759) saw a net inflow of 17.04 million from institutional investors, but a net outflow of 2.59 million from retail investors [3] - Bid Pharma (688073) had a net inflow of 1.08 million from institutional investors, while retail investors contributed a net inflow of 504,580 [3]